Incyte Reveals Promising TRuE-AD4 Results for Opzelura in Atopic Dermatitis

Incytes TRuE-AD4 study reveals Ruxolitinibs effectiveness as a topical medication for atopic dermatitis, with significant improvements in patient outcomes, highlighting its potential in health care.

• Incyte announced that the TRuE-AD4 study met its co-primary endpoints, showing 70.0% of patients on Ruxolitinib achieved EASI75 compared to 18.5% in the vehicle group (P<0.0001).
• The study also reported a 61.3% success rate in Investigators Global Assessment Treatment Success (IGA-TS) for Ruxolitinib users versus 13.6% for the control group, underscoring its efficacy.
• Patients receiving the topical medication demonstrated not only improvements in the EASI75 score but also significant relief from itch and dermatitis symptoms within eight weeks.